Trials agreement signed


23 August 2022
PREtec technology to be evaluated.

PLANT Health Care, a provider of biological products to global agriculture markets, has announced a trials agreement with Agrii UK under which Agrii will evaluate Plant Health Care's novel PREtec technology.
Plant Health Care has invested more than $25 million in its PREtec peptide technology platform ("Vaccines for Plants"). PREtec technology stimulates a plants' immune system to defend itself from a variety of abiotic stresses to improve plant health and yield. Derived from natural proteins, PREtec is an environmentally-friendly approach to protecting crops and is compatible with mainstream agricultural practices. 
The company plans to deliver at least one major launch of a PREtec product every year. Saori, which is recommended for the management of foliar diseases, was the first product to be launched from the PREtec platform, in Brazil in 2021. Similar launches of PREtec technology are planned for US markets in 2022 and 2023. 
Pressure on growers to move to more sustainable practices is very strong in Europe. As a result, Europe is now the largest market in the world for biological products. The commencement of field trials in the UK is a key step for Plant Health Care in preparing to launch a PREtec product in Europe.
With more than 140 thousand hectares of potatoes planted annually in the UK, the crop represents a significant target for Plant Health Care.  Extension to other crops in the UK is expected over time.
Jeff Tweedy, CEO of Plant Health Care said: ‟Plant Health Care has had a long-term successful relationship with Agrii for the distribution of our ProAct® product. I am very pleased now to continue the relationship to include trials for PREtec-based fertilizer products and explore the full potential of this new opportunity with a leading distributor in the agriculture sector in the UK."

Fertiliser use could be reduced with nature-based farming, shows major scientific study
'2022 potato season begins strongly'
Biostimulant trials support benefits
Content continues after advertisements